The biotechnology firm confirmed it remains on track to dose its first five patients in the combination trial by the end of July 2026, with initial data expected to follow in December. This study focuses on patients with chronic lymphocytic leukemia who have already been receiving zanubrutinib for at least one year, aiming to leverage a dual blockade of NF-kB to combat disease progression.
In section Releases
Curis Expands TakeAim CLL Study Sites and Secures Reverse Split Approval
Curis, Inc. has officially opened eleven clinical sites for its Phase 2 TakeAim CLL study, marking a significant step in testing emavusertib alongside zanubrutinib. Simultaneously, the company’s shareholders have approved a reverse stock split, a strategic move designed to help the firm regain compliance with Nasdaq’s minimum bid price requirements.
Following the special meeting held on June 25, 2026, stockholders authorized the Board of Directors to execute a reverse stock split at a ratio between 1-for-5 and 1-for-25. While the final ratio and implementation date remain pending, the move is a direct response to the Nasdaq $1.00 listing rule. CEO James Dentzer noted that these developments represent a dual focus on advancing the company’s clinical pipeline while stabilizing its standing on the public markets.
Comments (0)
No comments yet. Be the first!